- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03812263
A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pediatric non-randomized open-label Phase I/II clinical trial. The Phase I portion will include a safety evaluation and preliminary assessment of the efficacy of hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the ITGB2 gene in subjects with severe LAD-I. CD34+ cells will be transduced ex vivo with the therapeutic vector followed by cryopreservation. If the number of CD34+ cells that are available for infusion is at least 2x10e6 total CD34+ cells/kg, subjects will undergo myeloablative conditioning with intravenous busulfan. Subjects will then receive infusion of gene-corrected hematopoietic cells approximately 24 hours following the final busulfan dose.
The active agent is a self-inactivating lentiviral vector carrying the therapeutic ITGB2 gene, encoding for the human CD18 receptor (β2 integrin subunit). The therapeutic product is the subject's autologous hematopoietic stem cells that have been transduced with the lentiviral vector.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28009
- Hospital Infantil Universitario Niño Jesús (HIUNJ)
-
-
-
-
-
London, United Kingdom
- University College London Great Ormond Street Institute of Child Health
-
-
-
-
California
-
Los Angeles, California, United States, 90095-1489
- University of California, Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A confirmed diagnosis of severe LAD-I as demonstrated by flow cytometry indicating CD18 expression on <2% neutrophils (polymorphonuclear neutrophils (PMNs)). Subjects in which CD18+ PMNs are >2% will be considered eligible with <2% CD11a or CD11b expressing PMNs and if there is a documented ITGB2 mutation and clinical history consistent with LAD-I (or known family history).
- At least one (1) prior significant bacterial or fungal infection US NCI CTCAE, v5.0, Grade ≥2). This criterion is not required for subjects with documented family history who meet the above inclusion criteria.
- Age ≥3 months.
- Considered to be an appropriate candidate for autologous transplantation of hematopoietic stem cells.
- A competent custodial parent with legal capacity to execute an institutional review board (IRB)/ethics committee (EC)-approved consent form must be available to participate in the consent process. (Informed assent will be sought from capable subjects, in accordance with the directive of the IRB/EC and with local requirements).
- Ability to comply with trial procedures including investigational therapy and follow-up evaluations.
Exclusion Criteria:
- Availability of a medically-eligible human leukocyte antigen (HLA)-identical sibling donor transplant. Subjects may not be included in this trial as an alternative to a clinically-indicated and feasible HLA-matched sibling donor hematopoietic stem cell transplant. If an HLA-identical sibling is identified, but mobilized peripheral blood or bone marrow hematopoietic stem cell collection is not feasible (for example: donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo donation procedure because of medical impairments), then inclusion may be permitted per Investigator discretion.
Hepatic dysfunction as defined by either:
- Bilirubin >1.5× the upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5×ULN.
- Renal dysfunction as defined by either Grade 3 or higher abnormalities in serum sodium, potassium, calcium, magnesium or phosphate as defined by NCI CTCAE v5.0, or the requirement for either peritoneal dialysis or hemodialysis.
Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection).
- Oxygen saturation (by pulse oximetry) <90%.
- Evidence of active metastatic or locoregionally advanced malignancy (including hematologic malignancy) for which survival is anticipated to be less than 3 years.
- Serious infections with persistent bloodstream pathogens at time of trial entry. (Subjects with active infections (e.g., unresolved ulcerative lesions, skin or oral infections) are permitted as long as appropriate antibiotic therapy has been (or is being) administered).
- Any medical or other contraindication for both leukapheresis and bone marrow harvest procedure, as determined by the treating Investigator.
- Any medical or other contraindication for the administration of conditioning therapy, as determined by the treating Investigator.
- Significant medical conditions, including documented human immunodeficiency virus (HIV) infection, poorly-controlled diabetes, poorly-controlled hypertension, poorly-controlled cardiac arrhythmia or congestive heart failure; or arterial thromboembolic events (including stroke or myocardial infarction) within the 6 prior months.
- Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RP-L201
RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
|
CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0
Time Frame: 2 years
|
Evaluation of safety associated with treatment with RP-L201
|
2 years
|
Phase II: Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0
Time Frame: 2 years
|
Evaluation of safety associated with treatment with RP-L201
|
2 years
|
Phase II: Survival following infusion of RP-L201
Time Frame: 2 years
|
, as determined by the proportion of subjects alive at least 1-year post investigational product infusion without allogeneic HSCT and alive at age 2 (24 months) without allogeneic HSCT for subjects less than 1 year of age at study enrollment.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD18 expression after infusion of RP-L201
Time Frame: 2 years
|
Determination of the percentage of subjects in whom infusion of RP-L201 results in a change in the percentage of neutrophils expressing CD18 to at least 10%
|
2 years
|
Genetic correction after infusion of RP-L201
Time Frame: 2 years
|
Determination of the percentage of subjects in whom infusion of RP-L201 results in at least 10% of peripheral blood neutrophils carrying the therapeutic Chim-CD18-WPRE lentiviral vector provirus at 6 months post-infusion
|
2 years
|
Assessment of LAD-I-associated neutrophilia after infusion of RP-L201
Time Frame: 2 years
|
Evaluation of change to partially normal or to normal levels of LAD-I-associated neutrophilia
|
2 years
|
Assessment of skin rash or periodontal abnormalities after infusion of RP-L201
Time Frame: 2 years
|
Evaluation of resolution (partial or complete) of any underlying skin rash or periodontal abnormalities
|
2 years
|
Incidence of infections after infusion of RP-L201
Time Frame: 2 years
|
Determination of the incidence of significant infections, infection-related hospitalizations, and prolonged infection-related hospitalizations, comparing the incidences prior to investigational product infusion and subsequent to hematopoietic reconstitution.
|
2 years
|
Assessment of LAD-I-associated leukocytosis after infusion of RP-L201
Time Frame: 2 years
|
Evaluation of change to partially normal or to normal levels of LAD-I-associated leukocytosis
|
2 years
|
Assessment of overall survival after infusion of RP-L201
Time Frame: 2 years
|
Assessment of event-free survival (EFS) defined as survival without graft failure (GF) and without acute graft-versus-host disease (aGVHD) grade 2 to 4.
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Donald B Kohn, MD, University of California, Los Angeles
- Principal Investigator: Claire Booth, MBBS, PhD, MSc, University College London Great Ormond Street Institute of Child Health
- Principal Investigator: Julián Sevilla Navarro, MD, PhD, Hospital Infantil Universitario Niño Jesús
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-L201-0318
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukocyte Adhesion Defect - Type I
-
Rocket Pharmaceuticals Inc.WithdrawnLeukocyte Adhesion Defect - Type ISpain
-
Orpha LabsCompletedLeukocyte Adhesion Deficiency, Type II
-
National Cancer Institute (NCI)CompletedLeukocyte Adhesion Deficiency SyndromeUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedLeukocyte Adhesion Deficiency SyndromeUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedLeukocyte-Adhesion Deficiency SyndromeUnited States
-
AUG TherapeuticsRecruitingLeukocyte Adhesion DeficiencyUnited States
-
AUG TherapeuticsRecruitingLeukocyte Adhesion DeficiencyUnited States
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
Rocket Pharmaceuticals Inc.Enrolling by invitationLeukocyte Adhesion DeficiencySpain, United States, United Kingdom
-
Eunice Kennedy Shriver National Institute of Child...University of WashingtonUnknownWiskott-Aldrich Syndrome | Leukocyte Adhesion Deficiency Syndrome | X-Linked Agammaglobulinemia | X-Linked Hyper IgM SyndromeUnited States
Clinical Trials on RP-L201
-
Rocket Pharmaceuticals Inc.WithdrawnLeukocyte Adhesion Defect - Type ISpain
-
Ewha Womans UniversityCompletedOsteoarthritisKorea, Republic of
-
European Organisation for Research and Treatment...RecruitingAll Tumor TypesSpain, United Kingdom, Croatia, Belgium, France, Netherlands, Italy, Germany, Portugal, Austria, Cyprus, Czechia, Estonia, Greece, Lithuania, Poland, Romania, Slovenia, Switzerland, Serbia
-
Repare TherapeuticsDebiopharm International SARecruitingAdvanced Solid TumorUnited States, Canada, Denmark
-
DePuy InternationalTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedObsessive-Compulsive DisorderUnited States
-
Swiss Group for Clinical Cancer ResearchTerminated
-
DePuy InternationalTerminatedOsteoarthritisFrance, Switzerland, Germany, United Kingdom
-
Rocket Pharmaceuticals Inc.RecruitingPKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)United States
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group AUnited States